On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
Researchers conducted a systematic review to assess the effect of CPAP treatment for obstructive sleep apnea on secondary cardiovascular disease events.
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
Researchers evaluated whether patients with atherosclerotic cardiovascular disease (ASCVD) are utilizing high-intensity statins in their routine care of the disease.
In a prospective cohort study, researchers found associations between cardiovascular disease risk factors and the development of musculoskeletal disorders.
Researchers set out to determine the percentage of people in the United States with type 2 diabetes who meet the recommended criteria to use GLP-1 receptor agonists and SGLT-2 inhibitors as well as patients...
Among those with statin-intolerance, bempedoic acid, an inhibitor used to decrease elevated levels of low-density lipoprotein cholesterol, was also associated with a lower risk of major adverse...
The researchers evaluated the effects of two medications used for type 2 diabetes patients on reducing major cardiovascular events in both men and women.
Researchers sought to determine whether adults hospitalized for sepsis are at an increased risk of death or rehospitalization for cardiovascular events.
